The ‘Shark Tank’ investor and Dallas Mavericks owner’s remarks on Megyn Kelly’s podcast have got people talking. Mission accomplished.
Grow Your Business, Not Your Inbox
Stay informed and join our daily newsletter now!
2 min read
Like many public figures who identify as libertarian-leaning or ostensibly politically independent, Shark Tank investor and Dallas Mavericks owner Mark Cuban often walks a fine line between nuance and contrarianism. Take his recent New York Times Magazine interview with David Marchese, in which he reconciles his social-justice awakening with a mercenary eye on the bottom line.
That same duality was on display during his appearance this week on The Megyn Kelly Show podcast. Kelly dug deep into Cuban’s position on China, which enacted a yearlong ban on broadcasting NBA games that lifted just in time for the concluding two games of this year’s finals between the L.A. Lakers and Miami Heat.
Dallas Mavericks owner Mark Cuban said that he is “against human rights violations around the world,” though he is “OK doing business with China,” where more than one million Muslims have been imprisoned in concentration camps because “we have to pick our battles.”
Cuban’s comments came during an appearance on The Megyn Kelly Show podcast that aired Monday, in which the former Fox News and NBC News host asked why Cuban and the NBA wouldn’t “explicitly condemn” the numerous human rights abuses being carried out by the Chinese government, including the ethnic cleansing of Muslims, torture, forced labor, coercive population controls, forced abortions and forced sterilizations.
“I personally put a priority on domestic issues. I’m against human rights violations around the world,” Cuban said.
NEW YORK & MIAMI–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency (GHD), met its primary endpoint of improved treatment burden compared to GENOTROPIN® (somatropin) for injection administered once-daily.
Top-line results from the study demonstrated that treatment with somatrogon once-weekly improved the mean overall Life Interference total score after 12 weeks of treatment (8.63) compared to treatment with somatropin administered once-daily (24.13). The point estimate of the treatment difference was -15.49 (-19.71, -11.27 (95% CI); p<0.0001) in favor of somatrogon at the nominal 0.05 level. In addition, key secondary endpoints showed an overall benefit in treatment experience with the somatrogon once-weekly dosing regimen compared to the somatropin once-daily dosing regimen.
The business unit uses microorganisms to create solutions for human health and wellbeing
Gnosis by Lesaffre is striving to create a world that moves better, digests better, ages better, feels better, and, ultimately, lives better thanks to microorganisms and biotransformation. Earlier this month, Gnosis by Lesaffre unveiled its new, fully integrated brand and business strategy to help make this vision a reality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005855/en/
Gnosis by Lesaffre, a business unit of the Lesaffre Group, is unveiling its new, fully integrated brand and business strategy to the dietary supplement, functional food and beverage, and pharmaceutical industries. (Graphic: Business Wire)
Gnosis by Lesaffre, a business unit of the Lesaffre Group, harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The business unit collaborates with dietary supplement,